Immuneering Corporation
IMRXImmuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024.
NASDAQ
Healthcare
Biotechnology
$5.45
+0.12(2.25%)
52W $1.10 – $9.26
AI-generated
Immuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024.
$198MMkt Cap
—Rev TTM
-$46MNI TTM
-4.0xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 5, 2026Immuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024. The company generated no revenue, with total operating expenses of $59.4 million, primarily driven by $42.0 million in research and development and $17.3 million in general and administrative costs. The net loss per share was -$1.00. The...
What Changed Recently
Fundamentals
How The Business Makes Money
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Industry Biotechnology
Analyst View
Company Profile
CIK0001790340
ISINUS45254E1073
CUSIP45254E107
Phone617 500 8080
Address245 Main Street, Cambridge, MA, 02142, US
SEC EDGAR